

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 8-K

ELITE PHARMACEUTICALS INC /DE/  
Form 8-K  
August 05, 2004

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934

August 4, 2004

-----  
(Date of Report)

ELITE PHARMACEUTICALS, INC.

-----  
(Exact name of registrant as specified in its charter)

Delaware	333-45241	22-3542636
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

165 Ludlow Avenue, Northvale, New Jersey 07647

-----  
(Address of principal executive offices)

(201) 750-2646

-----  
(Registrant's telephone number, including area code)

Item 5. OTHER EVENTS AND REGULATION FD DISCLOSURE

The Registrant issued on August 4, 2004, a press release announcing that the exclusive right to negotiate a license from the Registrant's wholly owned subsidiary, Elite Laboratories, Inc., for the Registrant's proprietary abuse resistance technology for oxycodone, previously granted to Purdue Pharma L.P., has lapsed and as a result Registrant's intention to resume negotiations as to a license with other companies.

A copy of Registrant's press release is attached as Exhibit 99.1.

Item 7. FINANCIAL STATEMENTS AND EXHIBITS

- a) Not applicable.
- b) Not applicable.
- c) Exhibits

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 8-K

99.1. Press Release, dated August 4, 2004

-2-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 4, 2004

ELITE PHARMACEUTICALS, INC.

By: /s/ Bernard Berk

-----  
Name: Bernard Berk  
Title: Chief Executive Officer